Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Sangamo Therapeutics's ebitda for the twelve months ending Mar 31, 2026 was -$119.90M. For fiscal 2025 it was -$117.28M. The highest annual figure on record is -$18.83M in fiscal 2009.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$117.28M | – |
| FY2024 | Dec 31, 2024 | -$98.86M | – |
| FY2023 | Dec 31, 2023 | -$258.94M | – |
| FY2022 | Dec 31, 2022 | -$189.17M | – |
| FY2021 | Dec 31, 2021 | -$173.90M | – |
| FY2020 | Dec 31, 2020 | -$123.87M | – |
| FY2019 | Dec 31, 2019 | -$101.25M | – |
| FY2018 | Dec 31, 2018 | -$74.79M | – |
| FY2017 | Dec 31, 2017 | -$54.86M | – |
| FY2016 | Dec 31, 2016 | -$71.56M | – |
| FY2015 | Dec 31, 2015 | -$45.87M | – |
| FY2014 | Dec 31, 2014 | -$26.23M | – |
| FY2013 | Dec 31, 2013 | -$26.14M | – |
| FY2012 | Dec 31, 2012 | -$21.54M | – |
| FY2011 | Dec 31, 2011 | -$35.18M | – |
| FY2010 | Dec 31, 2010 | -$24.26M | – |
| FY2009 | Dec 31, 2009 | -$18.83M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$31.23M | – |
| Q4 FY2025 | Dec 31, 2025 | -$37.24M | – |
| Q3 FY2025 | Sep 30, 2025 | -$34.56M | -391.7% |
| Q2 FY2025 | Jun 30, 2025 | -$16.86M | – |
| Q1 FY2025 | Mar 31, 2025 | -$28.61M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.75M | – |
| Q3 FY2024 | Sep 30, 2024 | $11.85M | – |
| Q2 FY2024 | Jun 30, 2024 | -$35.84M | – |
| Q1 FY2024 | Mar 31, 2024 | -$50.12M | -332.9% |
| Q4 FY2023 | Dec 31, 2023 | -$60.23M | – |
| Q3 FY2023 | Sep 30, 2023 | -$100.92M | – |
| Q2 FY2023 | Jun 30, 2023 | -$119.32M | – |
| Q1 FY2023 | Mar 31, 2023 | $21.52M | – |
| Q4 FY2022 | Dec 31, 2022 | -$52.05M | – |
| Q3 FY2022 | Sep 30, 2022 | -$51.85M | – |
| Q2 FY2022 | Jun 30, 2022 | -$42.85M | – |
| Q1 FY2022 | Mar 31, 2022 | -$42.43M | – |
| Q4 FY2021 | Dec 31, 2021 | -$37.14M | – |
| Q3 FY2021 | Sep 30, 2021 | -$45.88M | – |
| Q2 FY2021 | Jun 30, 2021 | -$46.46M | – |
| Q1 FY2021 | Mar 31, 2021 | -$44.43M | – |
| Q4 FY2020 | Dec 31, 2020 | -$41.75M | -1671.3% |
| Q3 FY2020 | Sep 30, 2020 | -$2.34M | – |
| Q2 FY2020 | Jun 30, 2020 | -$36.57M | – |
| Q1 FY2020 | Mar 31, 2020 | -$43.21M | – |
| Q4 FY2019 | Dec 31, 2019 | $2.66M | – |
| Q3 FY2019 | Sep 30, 2019 | -$28.09M | – |
| Q2 FY2019 | Jun 30, 2019 | -$32.64M | – |
| Q1 FY2019 | Mar 31, 2019 | -$43.18M | – |
| Q4 FY2018 | Dec 31, 2018 | -$20.08M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.78M | – |
| Q2 FY2018 | Jun 30, 2018 | -$18.52M | – |
| Q1 FY2018 | Mar 31, 2018 | -$20.41M | – |
| Q4 FY2017 | Dec 31, 2017 | -$13.30M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.62M | – |
| Q2 FY2017 | Jun 30, 2017 | -$12.45M | – |
| Q1 FY2017 | Mar 31, 2017 | -$16.49M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.58M | – |
| Q3 FY2016 | Sep 30, 2016 | -$18.95M | – |
| Q2 FY2016 | Jun 30, 2016 | -$26.59M | – |
See a number that looks wrong?